Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Introduction Neoadjuvant chemotherapy for breast cancer treatment is prescribed to facilitate surgery and provide confirmation of drug-sensitive disease, and the achievement of pathological complete response (pCR) predicts improved long-term outcomes. Docosahexaenoic acid (DHA) has been shown to red...

Full description

Saved in:
Bibliographic Details
Main Authors: Sunita Ghosh, Anil Abraham Joy, Kerry Courneya, John R Mackey, Marnie Newell, Gilbert Bigras, Mirey Alvarez-Camacho, Susan Goruk, Alison Schmidt, Deborah Miede, Ann Chisotti, Lynne Postovit, Kristi Baker, Vera Mazurak, Richard Berendt, Wei-Feng Dong, George Wood, Sanraj K Basi, Karen King, Judith Meza-Junco, Xiaofu Zhu, Catherine Field
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/9/e030502.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/9/9/e030502.full

Similar Items